-
Information-Publications
-
Enhanced safety and antitumor efficacy of switchable dual chimeric antigen receptor-engineered T cells against solid tumors through a synthetic bifunctional PD-L1 …Details -
MicroRNA-155 regulates osteogenesis and bone mass phenotype via targeting S1PR1 geneDetails -
Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS‐STING SignalingDetails -
Enhancer RNA transcriptome-wide association study reveals an atlas of pan-cancer susceptibility eRNAsDetails -
Mechanisms underlying morphological and functional changes of cilia in fibroblasts derived from patients bearing ARL3T31A and ARL3T31A/C118F mutationsDetails -
Neutralization of SARS-CoV-2 BA. 2.86 and JN. 1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBDDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands
Back
